Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VII3a-IB
- Development stage
- Unknown
- Lead developer
- Instituto Butantan
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
VII3a-IB is an investigational inactivated, trivalent influenza vaccine adjuvanted with IB160, developed by Instituto Butantan in Brazil. The adjuvant, IB160, is a squalene-based oil-in-water emulsion (composed of squalene, Span 85, and Tween 80 in citrate buffer) similar to MF59®, developed with technical support from the Infectious Disease Research Institute (IDRI) and supported by the World Health Organization (WHO) and BARDA. The vaccine targets influenza virus hemagglutinin antigens to elicit a humoral immune response, specifically measured by hemagglutination inhibition titers. It is currently in Phase III clinical development in Brazil, where it is being compared to a high-dose inactivated trivalent influenza vaccine (VII-HD) for non-inferiority in adults aged 60 years and older.
- Other names
- inactivated trivalent influenza vaccine adjuvanted with IB160
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on VII3a-IB.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VII3a-IB.